ATE127024T1 - Immunogene komplexe, insbesondere iscoms. - Google Patents

Immunogene komplexe, insbesondere iscoms.

Info

Publication number: ATE127024T1
Authority: AT; Austria
Prior art keywords: pct; iscoms; immunogenic; quil; fractions
Prior art date: 1990-10-23

Application number

AT91918619T

Other languages

English (en)

Inventor

Gideon Frank Anne Kersten

Arjen Spiekstra

Gerrit Van De Werken

Eduard Coen Beuvery

Original Assignee

Nederlanden Staat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-23

Filing date

1991-10-23

Publication date

1995-09-15

1991-10-23 Application filed by Nederlanden Staat filed Critical Nederlanden Staat

1995-09-15 Application granted granted Critical

1995-09-15 Publication of ATE127024T1 publication Critical patent/ATE127024T1/de

Links

230000002163 immunogen Effects 0.000 title abstract 6
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 abstract 3
239000001397 quillaja saponaria molina bark Substances 0.000 abstract 3
229930182490 saponin Natural products 0.000 abstract 3
150000007949 saponins Chemical class 0.000 abstract 3
229930182558 Sterol Natural products 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
230000000890 antigenic effect Effects 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
230000008105 immune reaction Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003432 sterols Chemical class 0.000 abstract 1
235000003702 sterols Nutrition 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT91918619T 1990-10-23 1991-10-23 Immunogene komplexe, insbesondere iscoms. ATE127024T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NL9002314A NL9002314A (nl)	1990-10-23	1990-10-23	Immunogene complexen, in het bijzonder iscoms.

Publications (1)

Publication Number	Publication Date
ATE127024T1 true ATE127024T1 (de)	1995-09-15

Family

ID=19857870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91918619T ATE127024T1 (de)	1990-10-23	1991-10-23	Immunogene komplexe, insbesondere iscoms.

Country Status (10)

Country	Link
US (1)	US5620690A (de)
EP (1)	EP0555276B1 (de)
AT (1)	ATE127024T1 (de)
CA (1)	CA2094600C (de)
DE (1)	DE69112634T2 (de)
DK (1)	DK0555276T3 (de)
ES (1)	ES2075964T3 (de)
GR (1)	GR3017778T3 (de)
NL (1)	NL9002314A (de)
WO (1)	WO1992006710A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994010291A1 (en) *	1992-10-30	1994-05-11	Seed Capital Investment (Sci) B.V.	CULTURE CELLS OF $i(QUILLAJA SP.)
NL9301690A (nl) *	1993-08-12	1995-04-18	Seed Capital Investments	Verbindingen met adjuvans-activiteit.
AU1077795A (en) *	1993-09-30	1995-04-18	Seed Capital Investments (Sci) B.V.	Compounds with adjuvant activity
AUPM500494A0 (en) *	1994-04-12	1994-05-05	Minister For Agriculture & Rural Affairs For The State Of New South Wales, The	Composition for use in increasing mucosal immunity
AUPM873294A0 (en) *	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) *	1996-10-05	1996-11-20	Smithkline Beecham Plc	Vaccines
SE9600648D0 (sv) *	1996-02-21	1996-02-21	Bror Morein	Receptorbimdande enhet
AUPO517897A0 (en) *	1997-02-19	1997-04-11	Csl Limited	Chelating immunostimulating complexes
DE69840962D1 (de) *	1997-08-29	2009-08-20	Antigenics Inc	Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
GB9817052D0 (en) *	1998-08-05	1998-09-30	Smithkline Beecham Biolog	Vaccine
US7713942B2 (en)	2001-04-04	2010-05-11	Nordic Vaccine Technology A/S	Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
ATE409495T1 (de)	2001-04-04	2008-10-15	Nordic Vaccine Technology As	Polynukleotide-bindende komplexe die sterolen und saponine enthalten
SE0202110D0 (sv) *	2002-07-05	2002-07-05	Isconova Ab	Iscom preparation and use thereof
WO2004030696A2 (en) *	2002-10-02	2004-04-15	Nordic Vaccine Technology A/S	Composition for vaccination
SE0300795D0 (sv)	2003-03-24	2003-03-24	Isconova Ab	Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv)	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
CA2592627C (en) *	2005-01-20	2014-02-25	Isconova Ab	Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1873522B1 (de) *	2005-04-14	2014-08-13	Panasonic Healthcare Co., Ltd.	Verfahren zur bestimmung eines hämoglobinderivats sowie reagenszusammensetzung, testkit, analysevorrichtung und analysesystem zur verwendung in dem verfahren
CN102281892A (zh)	2009-01-13	2011-12-14	特朗斯吉有限公司	酿酒酵母线粒体核酸级分用于免疫刺激的用途
EP3311827B1 (de) *	2011-10-03	2023-01-04	Canqura Oncology Ab	Nanopartikel, verfahren zur herstellung und verwendung davon als träger für amphipatische oder hydrophobe moleküle in bereichen der medizin mit verbindungen im zusammenhang mit der krebsbehandlung und lebensmitteln
IL303336A (en)	2015-09-03	2023-08-01	Novavax Inc	Vaccine compositions having improved stability and immunogenicity
WO2019023196A1 (en)	2017-07-24	2019-01-31	Novavax, Inc.	METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
CA3092984A1 (en)	2018-03-19	2019-09-26	Novavax, Inc.	Multivalent influenza nanoparticle vaccines
US10953089B1 (en)	2020-01-27	2021-03-23	Novavax, Inc.	Coronavirus vaccine formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8205892D0 (sv) *	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3775783D1 (de) *	1986-01-14	1992-02-20	Nederlanden Staat	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) *	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
CA1331443C (en) *	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
NZ230747A (en) *	1988-09-30	1992-05-26	Bror Morein	Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) *	1989-10-24	1991-01-01	Coopers Animal Health Limited	Formation of adjuvant complexes
US5273965A (en) *	1992-07-02	1993-12-28	Cambridge Biotech Corporation	Methods for enhancing drug delivery with modified saponins

1990
- 1990-10-23 NL NL9002314A patent/NL9002314A/nl not_active Application Discontinuation
1991
- 1991-10-23 AT AT91918619T patent/ATE127024T1/de not_active IP Right Cessation
- 1991-10-23 CA CA002094600A patent/CA2094600C/en not_active Expired - Lifetime
- 1991-10-23 DE DE69112634T patent/DE69112634T2/de not_active Expired - Lifetime
- 1991-10-23 ES ES91918619T patent/ES2075964T3/es not_active Expired - Lifetime
- 1991-10-23 US US08/039,294 patent/US5620690A/en not_active Expired - Lifetime
- 1991-10-23 EP EP91918619A patent/EP0555276B1/de not_active Expired - Lifetime
- 1991-10-23 DK DK91918619.7T patent/DK0555276T3/da active
- 1991-10-23 WO PCT/NL1991/000211 patent/WO1992006710A1/en active IP Right Grant
1995
- 1995-10-18 GR GR950402880T patent/GR3017778T3/el unknown

Also Published As

Publication number	Publication date
EP0555276B1 (de)	1995-08-30
EP0555276A1 (de)	1993-08-18
DE69112634D1 (de)	1995-10-05
DE69112634T2 (de)	1996-02-08
GR3017778T3 (en)	1996-01-31
CA2094600C (en)	1998-12-08
ES2075964T3 (es)	1995-10-16
WO1992006710A1 (en)	1992-04-30
CA2094600A1 (en)	1992-04-24
NL9002314A (nl)	1992-05-18
DK0555276T3 (da)	1995-09-18
US5620690A (en)	1997-04-15

Publication	Publication Date	Title
ATE127024T1 (de)	1995-09-15	Immunogene komplexe, insbesondere iscoms.
DK602989A (da)	1989-11-29	Saponinadjuvans
HU9500571D0 (en)	1995-04-28	Retro-, inverso-, and retro-inverso synthetic peptide analogues
MY103182A (en)	1993-05-29	Vaccines against acquired immune deficiency syndrome.
ZA837603B (en)	1984-12-24	Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
NZ219113A (en)	1991-02-26	Hiv peptide containing epitope of the env protein
ES2138588T3 (es)	2000-01-16	Composiciones de vacunas que contienen liposomas.
HUP9903770A2 (hu)	2000-03-28	Eljárások és készítmények többepitópos antigének konformációjának megváltoztatására immunválasz kiváltása céljából
AU1800597A (en)	1997-08-28	Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
GR3029774T3 (en)	1999-06-30	Method of preparing a radioactive rhenium complex solution.
HRP940279B1 (en)	2000-12-31	IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
ATE188484T1 (de)	2000-01-15	Immunologisch mit hla homologe hiv protein epitope
ZA856655B (en)	1986-04-30	Cross-reactive and protective epitopes of circumsporozoite proteins
PL307170A1 (en)	1995-05-15	Vaccine against multicellular parasites
DE69229043D1 (de)	1999-06-02	Das durch den monoklonalen menschlichen antikörper 81av78 erkannte antigen ctaa 81av78
DE69615537D1 (en)	2001-10-31	Helicobacter pylori antigen
EP1020516A3 (de)	2000-10-11	Impfstoff-Antigene von Leptospira zur Vermeidung von Leptospirosis
MX9708226A (es)	1998-06-30	Vacunas que contienen una saponina y un esterol.

Legal Events

Date	Code	Title	Description
1996-03-15	UEP	Publication of translation of european patent specification
2012-01-15	EELA	Cancelled due to lapse of time